NCT07006805View on ClinicalTrials.gov

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

October 31, 2029

Conditions
Relapsing Multiple Sclerosis (RMS)Progressive Multiple Sclerosis (PMS)Multiple Sclerosis - Relapsing RemittingMultiple SclerosisMultiple Sclerosis (Relapsing Remitting)Multiple Sclerosis (MS) - Relapsing-remittingProgressive Multiple Sclerosis
Interventions
BIOLOGICAL

CABA-201

Single intravenous infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide

Sponsors

Lead Sponsor

Cabaletta Bio
All Listed Sponsors
lead

Cabaletta Bio

INDUSTRY